蒋晞博士，浙江大学医学院研究员、博士生导师。课题组主要研究肿瘤，特别是白血病的表观遗传学调节机制，以及针对表观遗传学机制的临床转化应用。 教育工作经历 2000-2005 复旦大学医学院 学士 2005-2010 复旦大学医学院 博士 （导师 马兰院士） 2010-2014 美国芝加哥大学（University of Chicago） 博士后 （导师 美国科学院院士Janet D. Rowley教授和陈建军教授） 2015-2017 美国辛辛那提大学（University of Cincinnati）助理教授（研究型）（Assistant Professor-Research） 2017-2018 美国希望城国家医疗中心（Beckman Research Institute of City of Hope）研究型助理教授（Assistant Research Professor, Step III） 2018- 浙江大学医学院 研究员、博士生导师 奖励荣誉 美国血液病学会年会杰出摘要奖 （Abstract Achievement Award for the American Society of Hematology (ASH) Annual Meeting）（2012，2014） 美国芝加哥大学肿瘤生物学委员会博士后奖学金 （The Committee on Cancer Biology (CCB) postdoctoral fellowship, the University of Chicago） （2013） 全美第8届肿瘤生物学联合会年会优秀报告奖 （Top 3 Abstract Award for 8th Annual Meeting of the Cancer Biology Training Consortium） （2012） 美国加百列天使肿瘤研究奖励基金（The Gabrielle's Angel Foundation Award） （2012） 上海市普通高校优秀博士毕业生 （2010）

肿瘤表观遗传学、转化医学、靶向治疗

研究方向 课题组致力于白血病的靶向治疗，主要研究方向为白血病表观遗传学调节网络，以及针对表观遗传学机制的临床转化应用。课题组的长期目标是通过与临床、制药的紧密合作，将基础研究发现的新疗法运用于临床，开发抗肿瘤靶向新药。具体方向包括 1、研究DNA和RNA 修饰在白血病化疗反应中的作用和调节机制； 2、探寻针对致癌DNA和RNA调控因子最佳靶位点的小分子拮抗剂； 3、筛选直接或间接作用于DNA和RNA修饰、且具潜在AML治疗作用的小分子化合物。

代表性论文（*并列一作; #通讯作者/并列通讯作者） (1) Zhao H, Lu J, Yan T, Han F, Sun J, Yin X, Chen L, Shen C, Wunderlich M, Yun W, Yang L, Chen L, Su D, Bohlander SK, Wang F, Mulloy JC, Li C, Chen J, Huang H, Jiang X#. (2022) Opioid receptor signaling suppresses leukemia through both catalytic and non-catalytic functions of TET2. Cell Rep. 38, 110253. PMID: 35081358. IF=9.42 (2) Han F, Zhao H, Lu J, Yun W, Yang L, Lou Y, Su D, Chen X, Zhang S, Jin H, Li X, Sun J, Huang H, Wang Q, Jiang X#. (2021) Anti-tumor effects of BDH1 in acute myeloid leukemia. Front Oncol. 11, 694594. PMCID: PMC8213090. IF=6.24 (3) Shen C, Sheng Y, Zhu AC, Robinson S, Jiang X*, Dong L, Chen H, Su R, Yin Z, Li W, Deng X, Chen Y, Hu YC, Weng H, Huang H, Prince E, Cogle CR, Sun M, Zhang B, Chen CW, Marcucci G, He C, Qian Z, Chen J. (2020) RNA demethylase ALKBH5 selectively promotes tumorigenesis and cancer stem cell self-renewal in acute myeloid leukemia. Cell Stem Cell. 27, 64-80. PMID: 32402250. IF=24.6 (4) Li C, Dong L, Su R, Bi Y, Qing Y, Deng X, Zhou Y, Hu C, Yu M, Huang H, Jiang X, Li X, He X, Zou D, Shen C, Han L, Sun M, Skibbe J, Ferchen K, Qin X, Weng H, Huang H, Song C, Chen J, Jin J. (2020) Homoharringtonine exhibits potent anti-tumor effect and modulates DNA epigenome in acute myeloid leukemia by targeting SP1/TET1/5hmC. Haematologica. 105, 148-160. PMID: 30975912. IF=9.94 (5) Huang H, Weng H, Zhou K, Wu T, Zhao BS, Sun M, Chen Z, Deng X, Xiao G, Auer F, Klemm L, Wu H, Zuo Z, Qin X, Dong Y, Zhou Y, Qin H, Tao S, Du J, Liu J, Lu Z, Yin H, Mesquita A, Yuan CL, Hu YC, Sun W, Su R, Dong L, Shen C, Li C, Qing Y, Jiang X, Wu X, Sun M, Guan JL, Qu L, Wei M, Muschen M, Huang G, He C, Yang J, Chen J. (2019) Histone H3 trimethylation at lysine 36 guides m6A RNA modification co-transcriptionally. Nature. 567, 414-419. PMID: 30867593. IF=50 (6) Sun Z, Xu X, He J, Murray A, Sun MA, Wei X, Wang X, McCoig E, Xie E, Jiang X, Li L, Zhu J, Chen J, Morozov A, Pickrell AM, Theus MH, Xie H. (2019) EGR1 recruits TET1 to shape the brain methylome during development and upon neuronal activity. Nat Commun. 10, 3892. PMID: 31467272. IF=14.9 (7) Su R, Dong L, Li C, Nachtergaele S, Wunderlich M, Qing Y, Deng X, Wang Y, Weng X, Hu C, Yu M, Skibbe J, Dai Q, Zou D, Wu T, Yu K, Weng H, Huang H, Ferchen K, Qin X, Zhang B, Qi J, Sasaki A, Plas DR, Bradner JE, Wei M, Marcucci G, Jiang X, Mulloy JC, Jin J, He C, Chen J. (2018) R-2HG exhibits anti-tumor activity by targeting FTO/MYC signaling. Cell. 11, 90-105. PMID: 29249359. IF=41.6 (8) Weng H, Huang H, Wu H, Qin X, Zhao BS, Dong L, Shi H, Skibbe J, Shen C, Hu C, Sheng Y, Wang Y, Wunderlich M, Zhang B, Dore L, Su R, Deng X, Ferchen K, Li C, Sun M, Lu Z, Jiang X, Marcucci G, Mulloy JC, Yang J, Qian Z, Wei M, He C, Chen J. (2018) METTL14 inhibits hematopoietic stem/progenitor differentiation and promotes leukemogenesis via mRNA m6A modification. Cell Stem Cell. 22, 191-205. PMID: 29290617. IF=24.6 (9) Huang H, Weng H, Sun W, Qin X, Shi H, Zhao BS, Mesquita A, Yuan CL, Hu YC, Hüttelmaier S, Strong J, Su R, Dong L, Sun M, Li C, Nachtergaele S, Wang Y, Hu C, Ferchen K, Greis KD, Jiang X, Qu L, Guan JL, He C, Yang J, Chen J. (2018) Recognition of RNA N6-methyadenosine by IXX2BP proteins Enhances mRNA Stability. Nat Cell Biol. 20,285-295. PMID: 29476152. IF=28.8 (10) Jiang Xi#, Hu C, Ferchen K, Nie J, Cui X, Chen CH, Cheng L, Zuo Z, Seibel W, He C, Tang Y, Skibbe JR, Wunderlich M, Reinhold WC, Dong L, Shen C, Arnovitz S, Ulrich B, Lu J, Weng H, Su R, Huang H, Wang Y, Li C, Qin X, Mulloy JC, Zheng Y, Diao J, Jin J, Li C, Liu PP, He C, Chen Y, Chen J. (2017) Targeted inhibition of TET1 transcription as a potent therapeutic strategy for acute myeloid leukemia. Nat Commun. 13, 2099. PMID: 29235481. IF=14.9 (11) Wang Y, Skibbe JR, Hu C, Dong L, Ferchen K, Su R, Li C, Huang H, Weng H, Huang H, Qin X, Jin J, Chen J, Jiang Xi#. (2017) ALOX5 exhibits anti-tumor and drug-sensitizing effects in MLL-rearranged leukemia. Sci Rep. 12, 1853. PMID: 28500307. IF=4.38 (12) Li Z, Weng H, Su R, Weng X, Zuo Z, Li C, Huang H, Nachtergaele S, Dong L, Hu C, Qin X, Tang L, Wang Y, Hong GM, Huang H, Wang X, Chen P, Gurbuxani S, Arnovitz S, Li Y, Li S, Strong J, Neilly MB, Larson RA, Jiang X, Zhang P, Jin J, He C, Chen J. (2017) FTO plays an oncogenic role in acute myeloid leukemia as a N6-methyladenosine RNA demethylase. Cancer Cell. 31, 127-141. PMID: 28017614. IF=31.7 (13) Jiang X, Hu C, Arnovitz S, Bugno J, Yu M, Zuo Z, Chen P, Huang H, Ulrich B, Gurbuxani S, Weng H, Strong J, Wang Y, Li Y, Salat J, Li S, Elkahloun AG, Yang Y, Neilly MB, Larson RA, Le Beau MM, Herold T, Bohlander SK, Liu PP, Zhang J, Li Z, He C, Jin J, Hong S, Chen J. (2016) miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia. Nat Commun. 26, 11452. PMID: 27116251. IF=14.9 (14) Jiang X#, Bugno J, Hu C, Yang Y, Herold T, Qi J, Chen P, Gurbuxani S, Arnovitz S, Strong J, Ferchen K, Ulrich B, Weng H, Wang Y, Huang H, Li S, Neilly MB, Larson RA, Le Beau MM, Bohlander SK, Jin J, Li Z, Bradner JE, Hong S, Chen J. (2016) Eradication of acute myeloid leukemia with FLT3 ligand-targeted miR-150 nanoparticles. Cancer Res. 76, 4470-4480. PMID: 27280396. IF=12.7 (15) Li Z, Chen P, Su R, Hu C, Li Y, Elkahloun AG, Zuo Z, Gurbuxani S, Arnovitz S, Weng H, Wang Y, Li S, Huang H, Neilly MB, Wang GG, Jiang X, Liu PP, Jin J, Chen J. (2016) PBX3 and MEIS1 cooperate in hematopoietic cells to drive acute myeloid leukemias characterized by a core transcriptome of the MLL-rearranged disease. Cancer Res. 76, 619-629. PMID: 26747896. IF=12.7 (16) Huang H, Jiang X, Wang J, Li Y, Song CX, Chen P, Li S, Gurbuxani S, Arnovitz S, Wang Y, Weng H, Neilly MB, He C, Li Z, Chen J. (2016) Identification of MLL-fusion/MYC/miR-26/TET1 signaling circuit in MLL-rearranged leukemia. Cancer Lett. 372, 157-165. PMID: 26791235. IF=8.67 (17) Li Z, Chen P, Su R, Li Y, Hu C, Wang Y, Arnovitz S, He M, Gurbuxani S, Zuo Z, Elkahloun AG, Li S, Weng H, Huang H, Neilly MB, Wang S, Olson EN, Larson RA, Le Beau MM, Zhang J, Jiang X, Wei M, Jin J, Liu PP, Chen J. (2015) Overexpression and knockout of miR-126 both promote leukemogenesis. Blood. 126, 2005-2015. PMID: 26361793. IF=23.6 (18) He Y, Jiang X and Chen J. (2014) The role of miR-150 in normal and malignant hematopoiesis. Oncogene. 33, 3887-93. PMCID: Pending. IF=9.87 (19) Huang H*, Jiang X*, Li Z, Li Y, Song CX, He C, Sun M, Chen P, Gurbuxani S, Wang J, Hong GM, Elkahloun AG, Arnovitz S, Wang J, Szulwach K, Lin L, Street C, Wunderlich M, Dawlaty M, Neilly MB, Jaenisch R, Yang FC, Mulloy JC, Jin P, Liu PP, Rowley JD, Xu M, He C and Chen J. (2013) TET1 plays an essential oncogenic role in MLL-rearranged leukemia. Proc Natl Acad Sci USA. 110, 11994-11999. PMCID: PMC3718141. IF=11.2 (20) Li Z, Herold T, He C, Valk PJ, Chen P, Jurinovic V, Mansmann U, Radmacher MD, Maharry KS, Sun M, Yang X, Huang H, Jiang X, Sauerland MC, Buchner T, Hiddemann W, Elkahloun A, Neilly MB, Zhang Y, Larson RA, Le Beau MM, Caligiuri MA, Dohner K, Bullinger L, Liu PP, Delwel R, Marcucci G, Lowenberg B, Bloomfield CD, Rowley JD, Bohlander SK, Chen J. (2013) Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study. J Clin Oncol. 31, 1172-1181. PMID: 23382473. IF=44.5